Clarence Ahlem's most recent trade in BioVie Inc was a trade of 2,476 COMMON STOCK done at an average price of $6.1 . Disclosure was reported to the exchange on Feb. 16, 2023.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
BioVie Inc | Clarence Ahlem | EVP Neuroscience Product Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.12 per share. | 16 Feb 2023 | 2,476 | 37,148 (0%) | 0% | 6.1 | 15,153 | COMMON STOCK |
BioVie Inc | Clarence Ahlem | EVP Neuroscience Product Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 39,624 | 39,624 (0%) | 0% | 0 | COMMON STOCK | |
BioVie Inc | Clarence Ahlem | EVP Neuroscience Product Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2021 | 124,167 | 124,167 | - | - | Stock Option (right to buy) |